The NIAID Division of Allergy, Immunology, and Transplantation's (DAIT) Radiation and Nuclear Countermeasures Program (RNCP) has been tasked with developing safe and effective medical countermeasures (MCMs) and biodosimetry tools for civilians, which can be used 24 hours or later post-exposure during a radiological or nuclear public health emergency. This Notice of Funding Opportunity (NOFO) is intended to elucidate sex-dependent effects that occur after radiation exposure. Historically, radiation studies predominantly utilized male animals, leading to an insufficient sex balance in preclinical study data that were not representative of the general population. Although this practice has changed over time and the inclusion of female animals has increased, the available radiation data for sex-dependent variables is still limited. While many studies demonstrate sex trends, they lack statistical power for definitive results and conclusions. This NOFO seeks to ensure studies are well-powered to include both female and male data to better understand underlying sex-related differences to advance radiation preclinical animal models, improve MCM development, increase the safety and efficacy of MCMs, and advance biomarker science to assess radiation injuries.
Due Date: September 6, 2023 Earliest Start: June 2024
|
Monday, May 8, 2023
RFA-AI-23-024: Sex Differences in Radiation Research: Models, Underlying Pathways, Biomarkers of Injury, and Medical Countermeasure Responses (U01 Clinical Trial Not Allowed)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment